Akero Therapeutics, INC Form 4 insider transactions
Akero Therapeutics CEO Andrew Cheng exercised stock options and sold shares on December 2, 2024, under a pre-arranged 10b5-1 trading plan.
Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 10,000 shares of common stock at a weighted average price of $32.131, as part of a pre-arranged trading plan.
Akero Therapeutics' Chief Development Officer, Catriona Yale, executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.
Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold 10,000 shares of common stock on November 6, 2024, according to a recent SEC filing.
Form 4: Akero Therapeutics COO Jonathan Young Executes Stock Option and Sells Shares Under 10b5-1 Plan
Akero Therapeutics' Chief Operating Officer, Jonathan Young, exercised stock options and sold shares of common stock on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Form 4: Akero Therapeutics CEO Andrew Cheng Executes Stock Options and Sells Shares Under 10b5-1 Plan
Akero Therapeutics CEO Andrew Cheng exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Form 4: Akero Therapeutics Executive Catriona Yale Executes Stock Options and Sells Shares Under 10b5-1 Plan
Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Form 4: Akero Therapeutics CEO Andrew Cheng Executes Stock Option and Sells Shares Under 10b5-1 Plan
Akero Therapeutics' CEO, Andrew Cheng, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Form 4: Akero Therapeutics COO Jonathan Young Executes Stock Option and Sells Shares Under 10b5-1 Plan
Jonathan Young, COO of Akero Therapeutics, exercised stock options and sold 40,000 shares of common stock under a pre-arranged 10b5-1 trading plan.
Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Jonathan Young, COO of Akero Therapeutics, reports the sale of 10,000 shares of common stock on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Catriona Yale, Chief Development Officer of Akero Therapeutics, reports the exercise of stock options and subsequent sale of shares under a pre-arranged trading plan.
Catriona Yale, Chief Development Officer of Akero Therapeutics, sold shares of common stock between September 16 and September 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Akero Therapeutics' Chief Operating Officer, Jonathan Young, reported the sale of 568 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Catriona Yale, Chief Development Officer of Akero Therapeutics, sold 637 shares of common stock on September 10, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Akero Therapeutics' Chief Financial Officer, William Richard White, sold 639 shares of common stock on September 10, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, sold 537 shares of common stock on September 10, 2024, to cover tax withholding obligations related to vesting restricted stock units.
Akero Therapeutics CEO Andrew Cheng sold 1,738 shares of common stock on September 10, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.
Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold shares of common stock on September 3, 2024, under a pre-arranged 10b5-1 trading plan.
Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares on September 3, 2024, according to a recent SEC filing.
Akero Therapeutics' Chief Financial Officer, William Richard White, executed stock option exercises and sales of common stock on August 26 and 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Catriona Yale, Chief Development Officer of Akero Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Akero Therapeutics CEO Andrew Cheng exercised stock options on August 16, 2024, acquiring 24,538 shares at $0.615 per share.
Jonathan Young, Chief Operating Officer of Akero Therapeutics, sold shares of the company's common stock on August 1, 2024, according to a Form 4 filing with the SEC.
William Richard White, CFO of Akero Therapeutics, recently executed a series of stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.
William Richard White, CFO of Akero Therapeutics, exercised stock options and sold shares on July 16, 2024, according to a Form 4 filing with the SEC.
Form 4: Akero Therapeutics Chief Scientific Officer Acquires Shares Through Employee Stock Purchase Plan
Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, acquired 1,064 shares of common stock through the company's Employee Stock Purchase Plan on June 28, 2024.
Catriona Yale, Chief Development Officer of Akero Therapeutics, reports acquiring 1,064 shares of common stock through the company's Employee Stock Purchase Plan.
Senior VP of Commercial Strategy at Akero Therapeutics, Patrick Lamy, reports acquiring 221 shares of common stock through the company's Employee Stock Purchase Plan.
Akero Therapeutics CEO Andrew Cheng acquired 1,064 shares of common stock through the company's Employee Stock Purchase Plan on June 28, 2024.